2012 highlights
- Signed alliance with Janssen Biotech – our biggest and broadest deal to-date
- Achieved Pfizer discovery milestone in therapeutic vaccine collaboration
- Progressed our alliances with Roche/Genentech and Medimmune
- Upgraded scale and capabilities of Phylomer discovery platform
- Advanced spin-off plans for JV with Cambridge University for target discovery and validation
- Extended IP estate with multiple new granted patents.
Phylogica has developed an integrated discovery platform to:
- Discover and validate new therapeutic targets found inside cells (via Phenomica)
- Develop therapeutic peptide leads against such targets
- Discover cell penetrating peptides that can deliver therapeutic cargoes into cells.
For further information please download PDF below:
